Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
Neratinib
67%
Breast Cancer
67%
Trastuzumab
62%
Metastatic Breast Cancer
48%
Human Epidermal Growth Factor Receptor 2-positive Breast Cancer (HER2-positive breast cancer)
39%
HER2 mutation
36%
Circulating Tumor DNA (ctDNA)
36%
Tumor
32%
Kinase Domain
31%
T-DM1
27%
ER+ Breast Cancer
25%
Phosphorylation
25%
Somatic mutation
22%
HER4
22%
Trastuzumab Emtansine
21%
Paclitaxel
20%
Her2neu
20%
Ceramide
20%
Adjuvant Trastuzumab
20%
Receptor Tyrosine Kinase
18%
Activating mutation
18%
ERBB2
17%
Epidermal Growth Factor Receptor Inhibitors (EGFRI)
17%
Diarrhea
16%
Loperamide
16%
HER2-positive
15%
Fulvestrant
15%
HER2-negative Breast Cancer
15%
HER2+
15%
Apoptosis Induction
14%
PIK3CA
14%
Phosphoproteomics
14%
Basket Study
14%
Genomic Characterization
13%
Cancer Genome Sequencing
13%
Breast Cancer Subtypes
13%
Endocrine Therapy
13%
HER2-positive Early-stage Breast Cancer
13%
Biomarker Analysis
13%
Footprinting
13%
Prognostic Biomarker
13%
Carboxyl Group
13%
Genetic Sequence Data
13%
HER2-mutant
13%
Apoptosis
12%
HER3
12%
Neoadjuvant
11%
DNA Sequencing
10%
EGF Receptor
10%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
85%
Kinase
71%
Phosphotransferase
71%
Receptor Tyrosine Kinase
59%
Genomics
59%
Clinical Trial
35%
phosphorylation
35%
C-Terminus
34%
Somatic Mutation
33%
Neratinib
31%
Tyrosine Kinase
30%
Estrogen Receptor
26%
Carcinogenesis
24%
Phosphoproteomics
20%
Genome Sequencing
19%
Cancer Genome Sequencing
19%
Gene Amplification
17%
Tumor Suppressor Protein
17%
Exome Sequencing
17%
ErbB
17%
Signal Transduction
15%
Conformation
15%
Tyrosine Kinase Inhibitor
15%
Oncogene
14%
Targeted Therapy
13%
Drug Resistance
13%
Chromatin
13%
MAP3K1
12%
Enzyme
12%
Signaling Protein
11%
Aromatase Inhibitor
11%
Indel
11%
Trastuzumab
10%
Lapatinib
10%
Point Mutation
10%
Peptide
10%
Cell Cycle
9%
Dimerization
9%
Autophosphorylation
9%
KRAS
9%
Gene Interaction
9%
GATA3
9%
Transcription
9%
Mutation Rate
9%
Missense Mutation
8%
DNA Sequence
8%
Gene Signature
8%
Tyrosine
8%
Loss of Function Mutation
8%
Gene Frequency
8%
Medicine and Dentistry
Breast Cancer
75%
Neratinib
54%
Metastatic Breast Cancer
53%
Trastuzumab
48%
Genetics
37%
Circulating Tumor DNA
34%
Adverse Event
22%
Diarrhea
21%
Clinical Trial
20%
Hormone Therapy
19%
Targeted Therapy
19%
Pertuzumab
18%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
16%
Neoplasm
16%
Malignant Neoplasm
16%
Loperamide
16%
Biological Marker
15%
Progression Free Survival
15%
Diseases
13%
Tyrosine-Kinase Inhibitor
13%
Recurrent Disease
10%
Adjuvant Therapy
10%
Epidermal Growth Factor Receptor
9%
Epidermal Growth Factor Receptor 2
9%
Metastatic Colorectal Cancer
9%
Estrogen
9%
Xenograft
9%
Quality of Life
9%
Molecular Profiling
8%
Capecitabine
8%
Fulvestrant
8%
Gamma Urogastrone
8%
Colestipol
8%
Colorectal Carcinoma
8%
Chemotherapy
8%
Triple Negative Breast Cancer
8%
Carcinogenesis
7%
Tumor
7%
Arm
7%
Cancer
7%
Estrogen Receptor
7%
Estrogen Receptor Positive Breast Cancer
6%
Zirconium 89
6%
Chloroplast DNA
6%
DNA Sequence
6%
Lobular Carcinoma
6%
Palbociclib
6%
Placebo
6%
Protein Tyrosine Kinase
6%
Enzalutamide
6%